Abstracts tagged "obesity and tofacitinib"

Abstract Number: 2737 • ACR/ARHP Annual Meeting 2015
Consistency of Treatment Effects Across Different High-Risk Clinical Phenotypes in the Tofacitinib Clinical Program
Jeffrey R. Curtis¹, Ara Dikranian², Alan Mendelsohn³, Koshika Soma⁴, Haiyun Fan³ and Chudy Nduaka³, ¹University of Alabama at Birmingham, Birmingham, AL, ²San Diego Arthritis Medical Clinic, San Diego, CA, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients (pts) with RA often have comorbidities that may affect treatment response.…